These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38552315)

  • 1. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI; Ruperto N; Ramanan AV; Horneff G; Minden K; Calvo Penades I; Alexeeva E; Cleary G; Stern SM; Kone-Paut I; Maldonado Velázquez MDR; Rabinovich CE; Remesal A; Silva CA; Nikishina I; Zucchetto M; Brockwell L; Gordon O; Nagel S; De Benedetti F;
    Rheumatology (Oxford); 2024 Sep; 63(9):2535-2546. PubMed ID: 38552315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
    Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
    Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Zhang X; Chen YC; Terao K
    Expert Rev Clin Pharmacol; 2017 May; 10(5):471-482. PubMed ID: 28293968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C; Tang X; Zhou Z; Sun L; Lu M; Zhou W; Yang S; Zheng W; Yu H; Tan W; Zhang J; Zhang Y; Kong Y; Xu J
    Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
    Frampton JE
    Paediatr Drugs; 2013 Dec; 15(6):515-31. PubMed ID: 24155139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    Pardeo M; Wang J; Ruperto N; Alexeeva E; Chasnyk V; Schneider R; Horneff G; Huppertz HI; Minden K; Onel K; Zemel L; Martin A; Koné-Paut I; Siamopoulou-Mavridou A; Silva CA; Porter-Brown B; Bharucha KN; Brunner HI; De Benedetti F;
    J Rheumatol; 2019 Sep; 46(9):1117-1126. PubMed ID: 30824645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
    Imagawa T; Yokota S; Mori M; Miyamae T; Takei S; Imanaka H; Nerome Y; Iwata N; Murata T; Miyoshi M; Nishimoto N; Kishimoto T
    Mod Rheumatol; 2012 Feb; 22(1):109-15. PubMed ID: 21667343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
    Brunner HI; Pacheco-Tena C; Louw I; Vega-Cornejo G; Alexeeva E; Appenzeller S; Chasnyk V; Griffin T; Suarez CN; Knupp-Oliveira S; Zeft A; Aviel YB; De Ranieri D; Gottlieb BS; Levy DM; Rabinovich CE; Silva CA; Spivakovsky Y; Uziel Y; Ringold S; Xu XL; Leu JH; Lam E; Wang Y; Lovell DJ; Martini A; Ruperto N;
    J Rheumatol; 2024 Nov; 51(11):1125-1134. PubMed ID: 39089836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.